Time filter

Source Type

Paris, France

Nanobiotix is a nanomedicine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies. The company is based in Paris. Wikipedia.

The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.

Nanobiotix, French National Center for Scientific Research and University of Bordeaux Segalen | Date: 2015-10-19

The present application relates to a method of monitoring the membrane permeabilization of liposome and the incidental release of a compound of interest.

Agency: Cordis | Branch: H2020 | Program: CSA | Phase: NMP-09-2014 | Award Amount: 2.00M | Year: 2015

ENATRANS main objective is to network and support SMEs in translation of nanomedicine in Europe by providing a one-stop-shop service to interact and share information, experience and advice with up-to-date information and interactive tools, but also enabling personal contacts. To be successful SMEs need to understand the requirements of the complex ecosystem made up of regulatory and reimbursement agencies, as well as the requirements of large industrial companies and clinical needs. ENATRANS will gather and provide information about approval processes, regulatory authorities and agencies, clinical and market data, and specific nanomedicine value chain analysis, relevant SME support projects and organisations. ENATRANS will convert this critical information in dedicated learning programs and tools dedicated to translation of nanomedicine. ENATRANS aims at implementing the concept of a Translation Advisory Board (TAB) as central element of the ETPN White Paper. A TAB will be set-up with senior experienced translation experts to guide R&D teams (in SMEs and research institutes) along the translation process to successfully make it to clinical trials and later to the market. Promising projects identified and supported by the TAB need access to clinical centers for first studies in patients, which are able to handle the specificity of new nanotechnology based therapeutics. In addition, financial resources are needed to go pass the regulatory and scale-up processes, which often require funding from investors and/or large companies. ENATRANS will build bridges to clinical trial centers, investors and large companies. Promising projects need guidance to successfully master privileged contacts with the medical, the business or the investment community. ENATRANS will deliver special coaching sessions prior to showcasing of promising projects. Partners in ENATRANS are VDI/VDE-IT, Nanobiotix, CEA, bioanalytik-muenster, Tel Aviv University, Fondazione Don Gnocchi, TecMinho.

Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP-2007-4.0-4 | Award Amount: 15.90M | Year: 2008

The demographic changes in Europe towards an aging society will coincide with increasing morbidity of the population. European citizens need improved access to state-of-the-art medical care especially in oncology and cardiology, while keeping expenditures on healthcare affordable. New therapeutic options such as externally triggered local drug release at the diseased area hold promise to solve urgent medical needs: improved treatment with reduced side effects, fewer burdens to the patient and faster recovery after intervention. Nanomedicine, the application of nanomaterials and nanotechnology to healthcare, will enable breakthroughs in clinical practice. SONODRUGS addresses clinical needs by developing novel drug delivery technologies for localised treatment of cardiovascular disease and cancer. SONODRUGS develops drug delivery concepts where drug release can be triggered by focused ultrasound induced pressure or temperature stimuli within the diseased tissue. New drug loaded nanocarriers will be designed for tailored drug delivery systems that respond to either of the two stimuli. Medical imaging, i.e. magnetic resonance imaging and ultrasound imaging, will be used to guide, follow and quantify the drug delivery process. Therapy efficacy using different drug delivery systems will be assessed in vitro and subsequently in preclinical studies. Starting form research on a broad range of materials and drugs, two nanocarriers will be finally selected, optimized and produced on a pilot scale in combination with image-guided delivery tools and methods. SONODRUGS binds expertise in materials research (Philips, TUE, GhentRGN, HBBG); material production (Nanobiotix, Lipoid); clinical knowledge in oncology (UTours, HBBG) and cardiology (UKB); in vitro and preclinical validation (UTours, ErasmusMC, UKB); research on imaging techniques (UCY, Philips, IMF); pharmacokinetics, toxicology and biodistribution (ULSOP, IPT).

The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.

Discover hidden collaborations